drugset / Trial / NCT07230106
A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a phase II, multicentre clinical study investigating HS-20093 or SHR2554 in combination with a Novel Hormonal Agent (NHA) for advanced prostate cancer. The trial comprises two cohorts.
Timeline
- Start
- 2025-12-08
- Primary completion
- 2028-12
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS-20093 | Other / unclassified | — | — |
| Subject | SHR2554 | Small molecule | — | — |
| Background | Abiraterone acetate | Small molecule | — | — |
| Background | Darotamine | Unknown | — | — |
| Background | Enzalutamide | Other / unclassified | — | — |
| Background | Rezvilutamide | Small molecule | — | — |